Clozapine-induced decrease in the production of reactive oxygen metabolites by monocytes in vitro may predict clinical response to clozapine in treatment-resistant schizophrenia

Human Psychopharmacology

Volumn 14, Issue 3, 1999, Pages 203-209

  Joffe, Grigori ^a   Nyberg, Peter ^b   Gross, Andres ^a   Appelberg, Björn ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Mjolbolsta Hospital   (Finland)

Author keywords

Clozapine; Monocytes; Reactive oxygen species; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; REACTIVE OXYGEN METABOLITE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESISTANCE; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0032956190     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199904)14:3<203::AID-HUP88>3.0.CO;2-1     Document Type: Article

References (41)

1. American Psychiatric Association (1987). DSM-III-R. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, revised. APA, Washington.
2. Banati, R., Gehrmann, J., Schubert, P. and Kreutzberg, G. (1993). Cytotoxicity of brain macrophages. Glia, 7, 111-118.
3. Bellavite, P. (1988). The superoxide-forming enzymatic system of phagocytes. Free Radical Biology and Medicine, 4, 225-261.
4. Benveniste, E. N. (1997). Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. Journal of Molecular Medicine, 75, 165-173.
5. Cadet, J. and Kahler, L. (1989). Free radical mechanisms in schizophrenia and tardive dyskinesia. Neuroscience and Biobehavior Reviews, 18, 457-467.
6. DeChatelet, L. R., Long, G. D., Shirley, P. S., Bass, D. A., Thomas, M. J., Hendersson, F. W. and Cohen, M. S. (1982). Mechanism of the luminol-dependent chemiluminescence of human neutrophils. Journal of Immunology, 129, 1589-1593.
7. DeLisi, L. (1997). Is schizophrenia a lifetime disorder of brain plasticity, growth and ageing? Schizophrenia Research, 23, 119-129.
8. Dillon, W. R. and Goldstein, M. (1984). Multivariate Analysis. Methods and Applications. John Wiley, New York.
9. Fischer, M. (1988). Monocyte and polymorphonuclear leukocyte toxic oxygen metabolite production in multiple sclerosis. Inflammation, 12, 123.
10. Fischer, V., Haar, J. A., Geriner, L., Lloyd, R. V. and Mason, R. P. (1991). Possible role of free radical formation in clozapine (Clozaril)-induced agranulocytosis. Molecular Pharmacology, 40, 846-853.
11. Ganguli, R., Brar, J. S., Chengappa, K. N. R., Yang, Z. W., Nimgaonkar, V. L. and Rabin, B. S. (1993). Autoimmunity in schizophrenia: a review of recent findings. Annals of Medicine, 25, 489-496.
12. Gur, R. E., Cowell, P., Turetsky, B., Gallacher, F., Cannon, T., Bilker, W. and Gur, R. C. (1998). A follow-up magnetic resonance imaging study of schizophrenia. Archives of General Psychiatry, 55, 145-152.
13. Hickey, W. (1991). Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathology, 1, 97-105.
14. Horrobin, D. F., Glen, A. I. M. and Vaddadi, K. (1994). The membrane hypothesis of schizophrenia. Schizophrenia Research, 13, 195-207.
15. Jesberger, J. and Richardson, S. (1991). Oxygen free radicals and brain dysfunction. International Journal of Neuroscience, 57, 1-17.
16. Joffe, G., Nyberg, P., Gross, A. and Appelberg, B. (1998). Is there an association between the effects of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic-resistant schizophrenia? Human Psychopharmacology, 13, 231-237.
17. Kane, J., Honigfeld, G., Singer, J., Meltzer, H. Y. and Clozaril Collaborative Study Group (1988). Clozapine for treatment-resistant schizophrenic. Archives of General Psychiatry, 45, 789-796.
18. Kay, S., Fiszbein, A. and Opler, L. (1987). The Positive and Negative syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
19. Leykin, I, Mayer R, Shinitzky, M. (1997). Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology, 37, 75-86.
20. Liu, Z. and Uetrecht, J. (1995). Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. Journal of Pharmacology and Experimental Therapeutics, 275, 1476-1483.
21. Maes, M., Bosmans, E., Kenis, G., De Jong, R., Smith, R. S. and Meltzer, H. Y. (1997). In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophrenia Research, 26, 221-225.
22. Mahadik, S. and Scheffer, R. (1996). Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins, Leukotrienes, EFAs, 55, 45-54.
23. McAdams, C. and Leonard, B. E. (1993). Neutrophil and monocyte phagocytosis in depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 17, 971-984.
24. Montgomery, S. and Asberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
25. Morrey, K. M., McLachlan, J. A., Serkin, C. D. and Bakouche, O. (1994). Activation of human monocytes by the pineal hormone melatonin. Journal of Immunology, 154, 2671-2680.
26. Müller, N. and Ackerheil, M. (1995a). The immune system and schizophrenia. In Stress, the Immune System and Psychiatry, Leonard, B. E. and Miller, K. (Eds), Wiley, Chichester, 137-164.
27. Müller, N. and Ackerheil, M. (1995b). Immunoglobulin and albumin contents of cerebrospinal fluid in schizophrenic patients: the relationship to negative symptomatology. Schizophrenia Research, 14, 223-228.
28. Nair, T. R., Christensen, J. D., Kumar, N, Mayhew EJ, Garver, D. L. (1997). Increasing ventricles in one of the schizophrenias. Presented in American Psychiatric Association Annual Meeting, May 17-22, San Diego, USA.
29. Nyberg, P. and Kockars, M. (1990). Effect of immunoglobulins on mineral dust-induced production of reactive oxygen metabolites by human macrophages. Inflammation, 14, 621-629.
30. Nyberg, P., Nordman, S. and Kockars, M. (1994). Increased mineral dust-induced production of reactive oxygen species by blood monocytes from patients with malignant diseases. APMIS, 102, 765-770.
31. Oehmichen, M., Domasch, D. and Wietholter, H. (1982). Origin, proliferation, and fate of cerebrospinal fluid cells. A review on cerebrospinal fluid cell kinetics. Journal of Neurology, 227, 145-150.
32. Oken, R. (1995). Towards a unifying hypothesis of neurodegenerative diseases and a concomitant rational strategy for their prophylaxis and therapy. Medical Hypotheses, 45, 341-342.
33. Owens, D. (1996). Adverse effects of antipsychotic agents: do newer agents offer advantages? Drugs, 51, 895-930.
34. Papadimitriou, J. and Ashman, R. (1989). Macrophages: current views on their differentiation, structure, and function. Ultrastructural Pathology, 13, 343-372.
35. Pieri, C., Recchioni, R., Moroni, F, Marcheselli F, Marra, M., Marinoni, S., Di, Primio R (1998). Melatonin regulates respiratory burst of human neutrophils and their depolarization. Journal of Pineal Research, 24, 43-49.
36. Reddy, R. and Yao, J. (1996). Free radical pathology in schizophrenia: a review. Prostaglandins, Leukotrienes, EFAs, 55, 33-43.
37. Smith, R. (1991). The immune system is a key factor in the ethiology of psychosocial disease. Medical Hypotheses, 34, 49-57.
38. Smith, R. (1992). A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Medical Hypotheses, 39, 248-257.
39. Sperner-Unterweger, B., Gaggl, S., Fleischhacker, W., Barnas, C., Herold, M. and Geissler, D. (1993). Effects of clozapine on hematopoiesis and the cytokine system. Biological Psychiatry, 34, 536-543.
40. Thery, C., Chamak, B. and Mallat, M. (1993). Neurotoxicity of brain macrophages. Clinical Neuropathology, 12, 288-290.
41. Wyatt, R. (1995). Early intervention for schizophrenia: can the course of the illness be altered? Biological Psychiatry, 38, 1-3.